Clinical Trials
11 trialsNCT02834013 2026-06-03
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03367741 2026-06-02
Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06638931 2026-04-15
ANTARES
Instituto do Cancer do Estado de São Paulo
Phase 2 Recruiting
NCT04065269 2026-02-20
ATARI
Institute of Cancer Research, United Kingdom
Phase 2 Active not recruiting
NCT03395080 2025-08-01
P204
Leap Therapeutics, Inc.
Phase 2 Completed
NCT04513665 2025-05-22
ZW25 in Women With Endometrial Cancers
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03241745 2024-12-27
A Study of Nivolumab in Selected Uterine Cancer Patients
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT04171700 2023-10-02
LODESTAR
pharmaand GmbH
Phase 2 Terminated
NCT03570437 2022-03-02
COPELIA
University of Manchester
Phase 2 Unknown
NCT03933761 2021-08-10
PRECISE
Australia New Zealand Gynaecological Oncology Group
Phase 2 Withdrawn
NCT00505492 2011-09-15
Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT/Chemotherapy
M.D. Anderson Cancer Center
Phase 2 Terminated